【24h】

ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation.

机译:ABO-组织血型在造血干细胞和实体器官移植中不相容。

获取原文
获取原文并翻译 | 示例
           

摘要

In contrast to solid organ transplantation (SOT), ABO-histo blood group incompatibility is of minor importance for hematopoietic stem cell transplantation (HSCT). Patients receiving ABO-incompatible HSCT are at an increased risk for immune-mediated hematological complications including immediate and delayed hemolysis, late red blood cell engraftment and pure red cell aplasia, but seem not to have a worse overall survival or increased transplant-related mortality. This review gives an overview of the immunological mechanisms leading to complications associated with ABO-incompatible HSCT and describes approaches to prevent them. The current organ shortage in SOT stimulates the exploration of new strategies to expand the donor pool including ABO-incompatible SOT and xenotransplantation. Here, we discuss the hypothesis that ABO-incompatible transplantation may be viewed as a human in vivo model for the humoral immune mechanisms of antigen-mismatched transplantation. ABO-incompatible HSCT and SOT provide excellent possibilities to analyze graft accommodation and transplantation tolerance. Understanding the underlying mechanisms of graft survival in ABO-incompatible transplantation may facilitate new strategies to overcome the immunological barriers in SOT and xenotransplantation.
机译:与实体器官移植(SOT)相比,ABO-组织血型不相容性在造血干细胞移植(HSCT)中次要重要性。接受ABO不相容HSCT的患者发生免疫介导的血液学并发症的风险增加,包括立即和延迟溶血,晚期红细胞移植和纯红细胞发育不全,但似乎总生存率没有下降或与移植相关的死亡率增加。这篇综述概述了导致与ABO不相容的HSCT相关的并发症的免疫机制,并描述了预防它们的方法。当前SOT的器官短缺刺激了探索扩大供体库的新策略的探索,包括与ABO不相容的SOT和异种移植。在这里,我们讨论的假设是ABO不兼容的移植可被视为抗原不匹配移植的体液免疫机制的人类体内模型。不兼容ABO的HSCT和SOT为分析移植物适应性和移植耐受性提供了极好的可能性。了解不兼容ABO的移植物中移植物存活的潜在机制可能有助于克服新的策略来克服SOT和异种移植中的免疫学障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号